#XLO

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates Xilio Therapeutics (NASDAQ: XLO) reported $35.8 million in gross proceeds from Series B warrant exercises and estimates $137.5 million in cash and cash equivalents as of December 31, 2025. The company said this funding extends its anticipated cash runway into the second quarter of 2027. Recent program updates include a development milestone for a masked antibody program under the AbbVie collaboration and nomination of a development candidate for a wholly owned masked T cell engager targeting CLDN18.2. Corporate changes include the appointment of Sara Bonstein as chair of the board. Anticipated next milestones include an IND submission for XTX501 in mid-2026 and initial Phase 1 data for XTX501 in H2 2027, subject to FDA clearance.

2 months ago

#XLO Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity

4 months ago

#XLO Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated

4 months ago

#XLO Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results Xilio Therapeutics (NASDAQ:XLO) reported Q2 2025 financial results and pipeline updates. The company's lead candidate vilastobart showed promising Phase 2 data with a 26% objective response rate in metastatic MSS colorectal cancer patients without liver metastases. The therapy demonstrated deep, durable responses and a differentiated safety profile.Financial highlights include $121.6 million in cash and cash equivalents, a net loss of $15.8 million, and revenue of $8.1 million. The company completed a follow-on offering raising $50.0 million in initial gross proceeds, with potential for additional $100.0 million from warrant exercises.Xilio expects to nominate development candidates for its masked T cell engager programs in H2 2025 and projects cash runway through Q3 2026.

7 months ago

#XLO Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

Cosmic Meta Digital

@cosmicmeta.bsky.social

7 months ago

XLOs are the future of digital monitoring: here's why Good uptime doesn’t guarantee great UX, that's why XLOs are redefining performance measurement

XLOs are the future of digital monitoring: here's why 7 years ago, Google started a radical movement that has changed digital experience. This is what happened next.. @cosmicmeta.ai #XLO

https://u2m.io/3ZlDvJDp

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Wed Jul 9th - #XLO #TAOX #SBC #RAIL #PAHC #OABI #KALA #INBX #GSIT #CNXN #AZTA #LDI #GGT #DK #CPUH #BGR #ALUR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering Xilio Therapeutics (XLO) has priced a $50.0 million public offering of pre-funded warrants and multiple series of warrants. The offering includes pre-funded warrants to purchase 66,676,000 shares, along with Series A, B, and C warrants, each to purchase the same number of shares. The combined offering price is $0.7499 per unit. The pre-funded warrants have a $0.0001 exercise price, while Series A, B, and C warrants have a $0.75 exercise price with different exercise periods and conditions. If all Series B and C warrants are exercised in cash, the company could receive additional gross proceeds of up to $100.0 million. The proceeds will be used for product candidate development and general corporate purposes. Leerink Partners is serving as the sole bookrunner, with the offering expected to close around June 5, 2025.

9 months ago

#XLO Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

Immuno-Oncology Biotech Xilio Therapeutics Unveils Complex Public Offering With Multiple Warrant Series Clinical-stage biotech Xilio plans complex warrant offering to advance cancer therapies. Leerink Partners leads unique multi-series structure. See full offering details.

9 months ago

#XLO Xilio Therapeutics Announces Proposed Public Offering

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

10 months ago

Just In: ( NASDAQ: #XLO ) Expected US Company Earnings on Tuesday, May 13th, 2025

0 0 0 0

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results Xilio Therapeutics (XLO) reported Q1 2025 financial results and pipeline updates. Key highlights include: promising Phase 2 data for vilastobart (anti-CTLA-4) combined with atezolizumab, showing 27% objective response rate in MSS CRC patients without liver metastases. The company is advancing multiple masked T cell engager programs, with first development candidates expected in H2 2025. Financially, Xilio ended Q1 with $89.1 million in cash, boosted by a $52 million upfront payment from AbbVie collaboration. Q1 revenue was $2.9M, with reduced R&D expenses at $8.3M (vs $10.4M in Q1 2024) and increased G&A expenses at $8.5M (vs $6.1M). Net loss improved to $13.3M from $17.2M year-over-year. Current cash runway extends into Q1 2026.

10 months ago

#XLO Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results Xilio Therapeutics (XLO) reported key pipeline and financial updates for Q4 and full year 2024. The company highlighted promising Phase 2 data for vilastobart, showing a 27% objective response rate in MSS CRC patients without liver metastases, with only 5% reporting colitis.The company announced a significant collaboration with AbbVie in Q1 2025, receiving $52.0 million in upfront payments, including a $10.0 million equity investment, with potential for up to $2.1 billion in milestone payments plus royalties.Financial highlights include: Cash position of $55.3 million as of December 31, 2024; License revenue of $6.3 million for 2024; R&D expenses decreased to $41.2 million from $52.1 million in 2023; Net loss improved to $58.2 million from $76.4 million in 2023. The company expects current cash runway into Q1 2026.

1 year ago

#XLO Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

1 year ago

🚀 Exciting times for #XLO! Trading at $1.14, Xilio Therapeutics is riding a bullish wave with strong momentum and volume spikes ahead of the Phase 2 trial update for Vilastobart. Consider a LONG position with targets at $1.20 & $1.25. Stay sharp, biotech can be volatile! 📈 #FeetrAI

0 0 0 0

1 year ago

🚀 Exciting times for #XLO! Positioned in a booming RNA market, it's showing bullish momentum with key moving averages and a positive MACD. 📈 Not overbought yet, so room to grow! Consider entry at $1.10, targeting $1.30 & $1.50. Stay alert for upcoming data! #Stocks #Biotech

0 0 0 0

1 year ago

🚀 Exciting times for #XLO! With bullish MACD and RSI in the 60s, Xilio Therapeutics is poised for a potential breakout. 📈 Entry at $1.15, targeting $1.25 & $1.35. Stay sharp with a stop loss at $1.05. Biotech buzz and RNA market growth could fuel the fire! 🔥 #FeetrAI

0 0 0 0

1 year ago

🚀 Exciting times for #XLO! With surging volume and optimism in RNA therapeutics, Xilio's Vilastobart updates could be a game-changer. Strong momentum but watch for pullbacks. Consider entry at $1.30, target $1.50-$1.60. Stay tuned for ASCO GI news! 📈 #Biotech #Stocks

1 0 0 0

1 year ago

NEWS: ( NASDAQ: #XLO ) Hot Trades Closing the Day on a High Note

0 0 0 0

1 year ago

News; ( NASDAQ: #XLO ) Hot Stocks Trading Higher on News- NXU, XLO, NKGN, AIFF, and WISA

0 0 0 0

1 year ago

Just In: ( NASDAQ: #XLO ) Hot Biotech Stocks in the News- Xilio Therapeutics, Aptose, and NKGen Biotech

0 0 0 0

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs Xilio Therapeutics (Nasdaq: XLO) announced three preclinical programs for masked T cell engagers targeting PSMA, CLDN18.2, and STEAP1. The company also entered into a collaboration agreement with AbbVie, receiving $52.0 million in upfront payments ($42.0M cash and $10.0M equity investment).The collaboration includes an exclusive option for AbbVie to develop masked cell engager molecules and a license for masked antibody-based immunotherapy, with potential additional payments up to $2.1 billion plus tiered royalties. Xilio's technology aims to improve T cell engager tolerability through tumor-selective activation.Development timelines include: PSMA candidate nomination in Q3 2025 (IND in Q1 2027), CLDN18.2 candidate in Q4 2025 (IND in Q2 2027), and STEAP1 candidate in H1 2026 (IND in H2 2027). The company's cash runway has been extended into Q1 2026.

1 year ago

#XLO Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

www.stocktitan.net/news/XLO/xilio-therapeut...

0 0 0 0

Major Cancer Breakthrough: AbbVie Invests $52M in Xilio's Revolutionary Tumor-Fighting Technology Xilio secures $52M upfront in strategic partnership with AbbVie to develop tumor-activated immunotherapies, with potential milestone payments of $2.1B.

1 year ago

#XLO AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

www.stocktitan.net/news/XLO/abb-vie-and-xil...

0 0 0 0

Major Oncology Partnership: AbbVie Commits $2.1B to Revolutionary Tumor-Fighting Technology AbbVie invests $52M upfront in Xilio's tumor-selective technology platform, targeting next-gen cancer treatments with potential $2.1B in milestone payments.

1 year ago

#ABBV #XLO AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

www.stocktitan.net/news/ABBV/abb-vie-and-xi...

0 0 0 0

1 year ago

Bearish vibes for #XLO! 📉 Trading at $0.7129 with low volume, RSI < 30 signals oversold. MACD & moving averages point down. Short entry at $0.71, targets: $0.68 & $0.65. Stop loss: $0.74. Cautious market + biotech volatility = defensive play. #FeetrAI #StockAnalysis

0 0 0 0

1 year ago

🚨 Bearish Alert on #XLO! Trading at $0.65, Xilio Therapeutics shows oversold conditions with a 14-day RSI of 32.5. Below key SMAs and negative MACD signal further weakness. Consider SHORT with targets at $0.60 & $0.55, stop loss at $0.70. 📉 #Biotech #FeetrAI

0 0 0 0

1 year ago

Bearish vibes for #XLO! 📉 Trading at $0.698, it's oversold with RSI <35 and a negative MACD. Downtrend alert: below 8-day EMA ($0.767) & 20-day SMA ($0.949). Short at $0.70, target $0.65/$0.60, stop loss $0.75. Cautious market, speculative play. #FeetrAI #StockAnalysis

0 0 0 0

1 year ago

Bearish vibes for #XLO! 📉 Trading at $0.6798, it's oversold with negative momentum. Short position alert: Enter around $0.68, target $0.65 & $0.60, stop loss at $0.70. Caution: Phase 2 trial news could shake things up! #FeetrAI #StockAnalysis #BiotechStocks

0 0 0 0

1 year ago

🚨 FeetrAI Alert: #XLO is in oversold territory with RSI at 24.78! 📉 Despite bearish momentum, a short-term bounce could be on the horizon. Consider a SHORT entry at $0.71, targeting $0.68 & $0.65. Stop loss at $0.73. Stay cautious in this volatile biotech space! 💡📊

0 0 0 0

1 year ago

🚨 FeetrAI Alert: #XLO is in the spotlight! Trading at $0.7037, it's showing bearish momentum with RSI <35 and a negative MACD. Low volume hints at reduced interest. Consider a SHORT position with targets at $0.68 & $0.65. Stop loss at $0.72. 📉 #BiotechVolatility

0 0 0 0